Morita Tatsuo
Department of Urology, Jichi Medical University, Tochigi, Japan.
Int Med Case Rep J. 2010 Apr 19;3:39-41. doi: 10.2147/imcrj.s9441. Print 2010.
A 67-year-old man was refered to our institution with a complaint of elevated serum prostate-specific antigen (PSA) level (54 ng/mL). Diagnosis was adenocarcinoma of the prostate with a Gleason score of 9, with bone metastasis (stageD2). He was treated with maximal androgen blockade followed by estramustine phosphate (EMP) because of the progression to hormone-refractory prostate cancer (HRPC). Leukocytosis over 20000/μL was repeatedly observed at each administration of EMP. This is the first case report of leukocytosis in response to EMP in an HRPC patient. The present case suggests that EMP could modulate leukocyte differentiation in HRPC patients.
一名67岁男性因血清前列腺特异性抗原（PSA）水平升高（54 ng/mL的）主诉转诊至我院。诊断为前列腺的腺癌，Gleason评分为9分，伴有骨转移（D2期）。由于进展为激素难治性前列腺癌（HRPC），他接受了最大限度雄激素阻断治疗，随后使用磷酸雌莫司汀（EMP）。每次给予EMP时均反复观察到白细胞增多超过20000/μL。这是HR的PC患者中首例关于EMP引起白细胞增多的病例报告。本病例提示EMP可调节HRPC患者的白细胞分化。
